PDCD1 and neoplasm: Tumor cells express PD-L1 inhibit T-cell activation by binding to PD-1 on the surface of T cells, and PD-1/PD-L1 inhibitors close these immune checkpoints, and enhancing T-cell activity and killing tumor cells (Masarwy et al., 2021).